7. Ikegami T, Yoshizumi T, Kato M, Yamamoto S, Fukuhara T, Matsuura Y, Nakamura S, Itoh S, Shirabe K and Maehara Y. Reduced-dose telaprevir-based triple antiviral therapy for recurrent hepatitis C after living donor liver transplantation. Transplantation. 98(9): 994-9, 2014
6. Fukuhara T, Wada M, Nakamura S, Ono C, Shiokawa M, Yamamoto S, Motomura T, Okamoto T, Okuzaki D, Yamamoto M, Saito I, Wakita T, Koike K and Matsuura Y. Amphipathic a-helices in apolipoproteins are crucial to the formation of infectious hepatitis C virus particles. PLoS Pathog. 10(12): e1004534, 2014
5．Konishi H, Motomura T, Matsumoto Y, Harimoto N, Ikegami T, Yoshizumi T, Soejima Y, Shirabe K, Fukuhara T and Maehara Y. Interferon-lambda4 genetic polymorphism is associated with the therapy respomse for hepatitis C virus rexurrence after living donor liver transplant. J Viral Hepat. 21(6): 397-404, 2014
4．Shiokawa M, Fukuhara T, Ono C, Yamamoto S, Okamoto T, Watanabe N, Wakita T and Matsuura Y. Novel permissive cell lines for complete propagation of hepatitis C virus. J Virol. 88(10): 5578-94, 2014
3．Ikegami T, Wang H, Yoshizumi T, Toshima T, Aishima S, Fukuhara T, Furusyo N, Kotoh K, Shimoda S, Shirabe K and Maehara Y. Strategies to treat interferon-induced graft dysfunction after living donor liver transplantation for hepatitis C. Hepatol Int. 8(2): 285-92, 2014
2．Toshima T, Shirabe K, Fukuhara T, Ikegami T, Yoshizumi T, Soejima Y, Ikeda T, Okano S and Maehara Y. Suppression of autophagy during liver regeneration impairs energy charge and hepatocyte senescence in mice. Hepatology. 60(1): 290-300, 2014
1．Ono C, Ninomiya A, Yamamoto S, Abe T, Wen X, Fukuhara T, Sasai M, Yamamoto M, Saitoh T, Satoh T, Kawai T, Ishii KJ, Akira S, Okamoto T and Matsuura Y. Innate immune response induced by baculovirus attenuates transgene expression in mammalian cells. J Virol. 88(4): 2157-67, 2014